New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT02705859
First seen Apr 17, 2026 · Last updated Jun 14, 2026 · Updated 8 times
Summary
This study tested a combination of two drugs (copanlisib and trastuzumab) in 26 adults with advanced HER2-positive breast cancer that had stopped responding to earlier treatments. The goal was to find the safest dose of copanlisib and see if the combination could shrink tumors or slow the disease. While the treatment aims to control the cancer, it is not a cure, and patients may need ongoing therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Trials Ireland Investigative Site
Cork, Ireland
-
Cancer Trials Ireland Investigative Site
Dublin, Ireland
-
Cancer Trials Ireland Investigative Site
Galway, Ireland
Conditions
Explore the condition pages connected to this study.